Models of the Month
Discover some of our popular patient-relevant models and gain a significant advantage in your team's preclinical oncology studies with time and cost savings.
Current Highlights
Access diverse and well-characterized tumor models, along with extensive profiling and pharmacologic data, empowering researchers like you to make confident and well-informed decisions during oncology drug discovery.
October 2026
BR9465 BR5017, BR5012, BR10564
Previous Model Highlights
Look back at our previous models to meet your research needs
In Vivo and In Vitro Models - Matched PDX/PDXO Model Series
GA0091, GA6833, GA0087, GA0089, GA0429, GA6891, GA6877, GA6866, GA6815, GA3102
Gastric Cancer Models
This model series provides matched gastric PDX and PDXO models that allow target expression, ADC activity, and in vitro-to-in vivo translation to be evaluated within the same underlying tumor biology.
In Vivo Models
LU9901, LU9906, and LU9903
In Vitro Models
LU11786B, LU9906B
Lung Cancer Models
An isogenic LU11786B lung cancer organoid pair engineered through TROP2 knockout to model Datroway resistance. The models demonstrate target-driven resistance, with loss of TROP2 abolishing detectable Datroway binding and associated DNA damage while retaining DXd payload activity. Clinically pretreated NSCLC PDX models LU9901, LU9906, and LU9903, with corresponding LU9906B organoid data, further recapitulate resistance observed in patients to osimertinib-based therapy and earlier ALK inhibitors.
In Vivo Models
BR9690 / BR9806 / BR9801
In Vitro Models
BR9690B / BR9806B / BR9801B
Longitudinal TNBC PDX/PDXO Series
Three matched PDX and organoid models established from consecutive tumor samples from the same TNBC patient during disease progression, including post-Trodelvy (sacituzumab govitecan) treatment. The models recapitulate resistance to Dato-DXd in both In Vitro and In Vivo.
In Vivo Models
CR9831
CR9831 is a colorectal cancer PDX derived from a heavily pretreated patient, featuring prior exposure to an anti-c-MET ADC.
In Vitro Models
PA20006B
Intra-patient organoid models allow for more accurate recapitulation of parental tumors. Highlighted here is primary site pancreatic organoid model PA20006B taken from a patient.
In Vivo and In Vitro Models - Matched PDX/PDXO Model Series
GA0091, GA6833, GA0087, GA0089, GA0429, GA6891, GA6877, GA6866, GA6815, GA3102
Gastric Cancer Models
This model series provides matched gastric PDX and PDXO models that allow target expression, ADC activity, and in vitro-to-in vivo translation to be evaluated within the same underlying tumor biology.
In Vivo Models
LU9901, LU9906, and LU9903
In Vitro Models
LU11786B, LU9906B
Lung Cancer Models
An isogenic LU11786B lung cancer organoid pair engineered through TROP2 knockout to model Datroway resistance. The models demonstrate target-driven resistance, with loss of TROP2 abolishing detectable Datroway binding and associated DNA damage while retaining DXd payload activity. Clinically pretreated NSCLC PDX models LU9901, LU9906, and LU9903, with corresponding LU9906B organoid data, further recapitulate resistance observed in patients to osimertinib-based therapy and earlier ALK inhibitors.
In Vivo Models
BR9690 / BR9806 / BR9801
In Vitro Models
BR9690B / BR9806B / BR9801B
Longitudinal TNBC PDX/PDXO Series
Three matched PDX and organoid models established from consecutive tumor samples from the same TNBC patient during disease progression, including post-Trodelvy (sacituzumab govitecan) treatment. The models recapitulate resistance to Dato-DXd in both In Vitro and In Vivo.
In Vivo Models
CR9831
CR9831 is a colorectal cancer PDX derived from a heavily pretreated patient, featuring prior exposure to an anti-c-MET ADC.
In Vitro Models
PA20006B
Intra-patient organoid models allow for more accurate recapitulation of parental tumors. Highlighted here is primary site pancreatic organoid model PA20006B taken from a patient.
In Vivo and In Vitro Models - Matched PDX/PDXO Model Series
GA0091, GA6833, GA0087, GA0089, GA0429, GA6891, GA6877, GA6866, GA6815, GA3102
Gastric Cancer Models
This model series provides matched gastric PDX and PDXO models that allow target expression, ADC activity, and in vitro-to-in vivo translation to be evaluated within the same underlying tumor biology.
In Vivo Models
LU9901, LU9906, and LU9903
In Vitro Models
LU11786B, LU9906B
Lung Cancer Models
An isogenic LU11786B lung cancer organoid pair engineered through TROP2 knockout to model Datroway resistance. The models demonstrate target-driven resistance, with loss of TROP2 abolishing detectable Datroway binding and associated DNA damage while retaining DXd payload activity. Clinically pretreated NSCLC PDX models LU9901, LU9906, and LU9903, with corresponding LU9906B organoid data, further recapitulate resistance observed in patients to osimertinib-based therapy and earlier ALK inhibitors.
In Vivo Models
BR9690 / BR9806 / BR9801
In Vitro Models
BR9690B / BR9806B / BR9801B
Longitudinal TNBC PDX/PDXO Series
Three matched PDX and organoid models established from consecutive tumor samples from the same TNBC patient during disease progression, including post-Trodelvy (sacituzumab govitecan) treatment. The models recapitulate resistance to Dato-DXd in both In Vitro and In Vivo.
In Vivo Models
CR9831
CR9831 is a colorectal cancer PDX derived from a heavily pretreated patient, featuring prior exposure to an anti-c-MET ADC.
In Vitro Models
PA20006B
Intra-patient organoid models allow for more accurate recapitulation of parental tumors. Highlighted here is primary site pancreatic organoid model PA20006B taken from a patient.
In Vivo and In Vitro Models - Matched PDX/PDXO Model Series
GA0091, GA6833, GA0087, GA0089, GA0429, GA6891, GA6877, GA6866, GA6815, GA3102
Gastric Cancer Models
This model series provides matched gastric PDX and PDXO models that allow target expression, ADC activity, and in vitro-to-in vivo translation to be evaluated within the same underlying tumor biology.
In Vivo Models
LU9901, LU9906, and LU9903
In Vitro Models
LU11786B, LU9906B
Lung Cancer Models
An isogenic LU11786B lung cancer organoid pair engineered through TROP2 knockout to model Datroway resistance. The models demonstrate target-driven resistance, with loss of TROP2 abolishing detectable Datroway binding and associated DNA damage while retaining DXd payload activity. Clinically pretreated NSCLC PDX models LU9901, LU9906, and LU9903, with corresponding LU9906B organoid data, further recapitulate resistance observed in patients to osimertinib-based therapy and earlier ALK inhibitors.
In Vivo Models
BR9690 / BR9806 / BR9801
In Vitro Models
BR9690B / BR9806B / BR9801B
Longitudinal TNBC PDX/PDXO Series
Three matched PDX and organoid models established from consecutive tumor samples from the same TNBC patient during disease progression, including post-Trodelvy (sacituzumab govitecan) treatment. The models recapitulate resistance to Dato-DXd in both In Vitro and In Vivo.
In Vivo Models
CR9831
CR9831 is a colorectal cancer PDX derived from a heavily pretreated patient, featuring prior exposure to an anti-c-MET ADC.
In Vitro Models
PA20006B
Intra-patient organoid models allow for more accurate recapitulation of parental tumors. Highlighted here is primary site pancreatic organoid model PA20006B taken from a patient.
In Vivo and In Vitro Models - Matched PDX/PDXO Model Series
GA0091, GA6833, GA0087, GA0089, GA0429, GA6891, GA6877, GA6866, GA6815, GA3102
Gastric Cancer Models
This model series provides matched gastric PDX and PDXO models that allow target expression, ADC activity, and in vitro-to-in vivo translation to be evaluated within the same underlying tumor biology.
In Vivo Models
LU9901, LU9906, and LU9903
In Vitro Models
LU11786B, LU9906B
Lung Cancer Models
An isogenic LU11786B lung cancer organoid pair engineered through TROP2 knockout to model Datroway resistance. The models demonstrate target-driven resistance, with loss of TROP2 abolishing detectable Datroway binding and associated DNA damage while retaining DXd payload activity. Clinically pretreated NSCLC PDX models LU9901, LU9906, and LU9903, with corresponding LU9906B organoid data, further recapitulate resistance observed in patients to osimertinib-based therapy and earlier ALK inhibitors.
In Vivo Models
BR9690 / BR9806 / BR9801
In Vitro Models
BR9690B / BR9806B / BR9801B
Longitudinal TNBC PDX/PDXO Series
Three matched PDX and organoid models established from consecutive tumor samples from the same TNBC patient during disease progression, including post-Trodelvy (sacituzumab govitecan) treatment. The models recapitulate resistance to Dato-DXd in both In Vitro and In Vivo.
In Vivo Models
CR9831
CR9831 is a colorectal cancer PDX derived from a heavily pretreated patient, featuring prior exposure to an anti-c-MET ADC.
In Vitro Models
PA20006B
Intra-patient organoid models allow for more accurate recapitulation of parental tumors. Highlighted here is primary site pancreatic organoid model PA20006B taken from a patient.
Ready To Collaborate?
Access a diverse range of tumor models and data, all in one integrated platform, empowering your research endeavors.
Boasting over 2,500 Patient-Derived Xenograft (PDX) models — the world's largest.
Our collection also includes 100+ immuno-oncology murine models, 600+ organoid models, 1,000+ cancer cell lines, and 200+ CDX models, ensuring a perfect fit for your research needs.
